By targeting mTOR directly and enhancing cancer cell apoptosis, CuB not only inhibits tumor growth but also boosts the effectiveness of cisplatin therapy, suggesting it could be used alone or in combination with other chemotherapeutics to improve treatment outcomes in cisplatin-resistant ovarian cancer (114). This evidence concerns the gene MTOR and neoplasm.